Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine
- Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
- Preparing DNA for sequencing libraries is complex and prone to human error, which can interfere with accurate sequencing results
- The new AVENIO Edge System is a fully-automated solution for the sample preparation workflow, from DNA sample input to the output of sequencing-ready libraries, and supports more comprehensive testing with consistent and high quality results for precision medicine for the future
Basel, 13 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the AVENIO Edge System, a core component of Roche’s strategy to advance sequencing technologies. Built on best-in-class foundational capabilities to deliver a fully-automated, integrated sequencing solution.
The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment and quantification steps that deliver integrated, end-to-end control with reliable, consistent high-quality results.
“Roche is committed to developing diagnostic solutions with the goal of providing the healthcare community with faster and more accurate medical information to predict risk and detect disease,” said Thomas Schinecker, CEO Roche Diagnostics. “We are pleased to offer next-generation sequencing laboratories and translational researchers the new automated AVENIO Edge System that aims to drastically reduce human error and help ensure fast, reliable and accurate results.”
Next-generation sequencing samples are precious. Every step of sample preparation has the potential to impact results. The AVENIO Edge System’s high reproducibility and low error rate can support the goal of reducing the number of rejected samples which otherwise might have to be re-collected.
The new AVENIO Edge System offers ready-to-use components in addition to customisable workflow parameters, making it a scalable, cost-efficient solution for sequencing laboratories seeking high performance and agility. With a setup to initiation of 20 minutes, this walkaway system demonstrated more than a 96 percent lower error opportunity and an 84 percent reduction in hands-on time.
The AVENIO Edge System will be available at select locations worldwide with timelines that vary country by country.
About the AVENIO Edge System
The AVENIO Edge System is Class I, In Vitro Diagnostics (IVD), 510(k) exempt, in the US. It is Class A in the EU in accordance with EU Regulation 2017/746 (IVDR) of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices. At launch, the AVENIO Edge Instrument can be used for Research Use Only (RUO) workflows. Consumables are General Laboratory Use (GLU). Compatible reagents and workflows are Research Use Only (RUO). Not for use in diagnostic procedures.
The AVENIO Edge System simplifies next-generation sequencing (NGS) and elevates automated sample preparation with integrated workflows, reagents, barcoded consumables and connectivity to enable reliable, high-quality results and the freedom to do more.
The AVENIO Edge System delivered high sequencing performance and demonstrated high uniformity, specificity and reproducibility in our in-house technical validation and early customer studies. At an early evaluation study site, the AVENIO Edge System replaced 384 manual steps while preparing 24 DNA libraries in one run versus manually preparing 24 DNA libraries.
The AVENIO Edge System is a fully automated liquid handling technology consisting of all-in-one hardware and traceable solutions that guides the operators through the process, provides real-time tracking of samples and delivery of the results to the laboratory information system (LIS). It is intended for routine laboratory tasks and designed to support multiple library prep, target enrichment and quantification workflow steps with customizable parameters. The AVENIO Edge System offers a wide set of modular, barcoded and ready-to-run reagents in addition to customizable workflow parameters, making it a scalable, cost-efficient solution for sequencing laboratories seeking high performance and agility.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
|Dr. Nicolas Dunant|
Phone: +41 61 687 05 17
Phone: +41 79 935 81 48
|Dr. Barbara von Schnurbein |
Phone: +41 61 687 89 67
Phone: +41 61 682 28 31
Phone: +41 79 327 54 74
Phone: +41 61 687 43 05
Roche Investor Relations
|Dr. Karl Mahler|
Phone: +41 61 68-78503
|Dr. Bruno Eschli|
Phone: +41 61 68-75284
|Dr. Sabine Borngräber|
Phone: +41 61 68-88027
|Dr. Gerard Tobin|
Phone: +41 61 68-72942
Dr. Birgit Masjost
Phone: +41 61 68-84814
Investor Relations North America
Phone: +1 650 225 3217
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
DNO Receives 10 Awards in Norway's APA Licensing Round18.1.2022 15:54:11 CET | Press release
Oslo, 18 January 2022 – DNO ASA, the Norwegian oil and gas operator, today announced that its wholly-owned subsidiary DNO Norge AS has been awarded participation in 10 exploration licenses, of which three are operatorships, under Norway's Awards in Predefined Areas (APA) 2021 licensing round. Of the 10 new licenses, six are in the North Sea and four in the Norwegian Sea. At yearend 2021, DNO held interests in 73 licenses offshore Norway, of which 17 were operated by the Company. The new awards under the APA 2021 licensing round include: PL 586 B: Neptune Energy Norge AS (operator), Suncor Energy Norge AS, Vår Energi AS, DNO Norge AS (7.5%) PL 923 B: Equinor Energy AS (operator), Petoro AS, Wellesley Petroleum AS, DNO Norge AS (20%) PL 969 B: A/S Norske Shell (operator), Spirit Energy Norway, DNO Norge AS (45%) PL 1007 B: DNO Norge AS (operator, 40%), OMV (Norge) AS, Equinor Energy AS, Spirit Energy Norway AS PL 1145: DNO Norge AS (operator, 60%), Aker BP ASA PL 1146: ConocoPhillips Ska
AGC Biologics Names Regina Choi-Rivera New General Manager of Boulder, Colorado Mammalian Production Facility18.1.2022 15:05:00 CET | Press release
Boulder, Colo., Jan. 18, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations. “We’re incredibly excited that Ms. Choi-Rivera is joining AGC Biologics as the General Manager at our Boulder facility. She brings tremendous experience in both GMP manufacturing and project management,” said AGC Biologics Executive Vice President of U.S. Operations, J.D. Mowery. “Her breadth of knowledge and proven leadership give me great confidence that she is the right leader for our team, as well as our customers.” Ms. Choi-Rivera brings more than 25 years of experience in the biotech industry to this role and joins AGC Biologics after working for Samsun
Solidium’s CEO to change18.1.2022 14:01:05 CET | Press release
Solidium’s CEO, Antti Mäkinen, will leave his position as the CEO of Solidium on 31st May 2022. Mäkinen, 60, has acted as CEO of the company since year 2017. “The past five years have been rewarding and I have had the opportunity to work with an excellent team and great portfolio companies. Solidium has an established position and a strong track in growing shareholder value”, says Mäkinen. Antti Mäkinen has acted as a Board Member and Chairman of the Shareholders’ Nomination Committee in many of Solidium’s portfolio companies. He is still nominated this Spring in the Annual General Meetings i.a. as the Chairman of the Board in Stora Enso and a Member of the Board in Metso Outotec. The Chairman of the Board of Solidium, Harri Sailas, would like to thank Mäkinen for his work both in charge of Solidium and as Solidium’s representative in the portfolio companies. “In Antti Mäkinen’s steering, Solidiums position has stabilized and the company has been more active both as an owner and in mak
Solidiums verkställande direktör avgår18.1.2022 14:01:05 CET | Pressemelding
Solidiums verkställande direktör Antti Mäkinen lämnar sin post som VD den 31 maj 2022. Mäkinen, 60, har verkat i företagets ledning från och med år 2017. ”De senaste fem åren har varit givande och jag har fått arbeta med ett utmärkt team och fina portföljbolag. Solidium har en stabil position och bevisad förmåga att öka innehavens ägarvärde”, säger Mäkinen. Antti Mäkinen har verkat i flera av Solidiums portföljbolag som styrelsemedlem och som ordförande i aktieägarnas nomineringskommitté. Han är fortfarande nominerad i vårens bolagsstämmor bland annat som styrelseordförande i Stora Enso och styrelsemedlem i Metso Outotec. Solidiums styrelseordförande Harri Sailas tackar Mäkinen för arbetet både inom Solidiums ledning och som representant i Solidiums portföljbolag. ”Under ledning av Antti Mäkinen har Solidiums position etablerat sig och företaget har aktiverat sig både som ägare och vid att göra nya placeringar. Hans agerande har väckt uppskattning i alla företagets intressegrupper”, sä
RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.1.2022 11:30:00 CET | Press release
AuctionAuction resultsAuction date2022-01-18Maturity2024Tendered volume, SEK mln750 +/- 750Offered volume, SEK mln1593Volume bought, SEK mln1500Number of bids19Number of accepted bids19 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln720205600Volume bought, SEK mln627205600Number of bids4310Number of accepted bids4310Average DM-0.166-0.139-0.129-Lowest accepted DM-0.179-0.160-0.129-Highest DM-0.129-0.139-0.129-Accepted at lowest DM0.814100.00100.00- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln4081001000Volume bought, SEK mln4081001000Number of bids7310Number of accepted bids7310Average DM-0.133-0.129-0.140-Lowest accepted DM-0.160-0.129-0.140-Highest DM-0.120-0.129-0.140-Accepted at lowest DM100.00100.00100.00-
Aspo subsidiary ESL Shipping continues fleet renewal in accordance with its strategy by selling the barge Espa18.1.2022 11:15:00 CET | Press release
Aspo Plc Press Release January 18, 2022, at 12.15 p.m. Aspo subsidiary ESL Shipping continues fleetrenewal in accordance with its strategy by selling the barge Espa Aspo’s ESL Shipping continues fleet renewal by selling its smallest, 9000 dwt towable barge Espa to Raduga Shipping and Trading OÜ. The transaction was concluded and Espa subsequently delivered to her new owner today 18th of January. A sales gain of approximately 1.4 million euros will be recorded in the profit of ESL Shipping’s first quarter. Espa was built in 1987 as the last vessel of the Vuosaari shipyard in Helsinki. She was designed and equipped for efficient transportation and lightering of energy coal cargoes to powerplants in Helsinki. In recent years she was mainly used for cement industry transport demand. She also spent one summer as a floating beach volley field in Helsinki. Peculiarities in Finnish shipping policy led to increasing cost of barge towing tugboats, as tugboat crew could not receive state support
RESULT OF RIKSBANK CERTIFICATE SALE18.1.2022 10:15:00 CET | Press release
AuctionAuction resultsAuction date2022-01-18Start date2022-01-19Maturity date2022-01-26Interest rate, %0.00Offered volume, SEK bn570.0Total bid amount, SEK bn2737.4Accepted volume, SEK bn570.0Number of bids16Percentage alloted, %20.823